IL308063A - Expanded dosage regimens for integrin inhibitors - Google Patents
Expanded dosage regimens for integrin inhibitorsInfo
- Publication number
- IL308063A IL308063A IL308063A IL30806323A IL308063A IL 308063 A IL308063 A IL 308063A IL 308063 A IL308063 A IL 308063A IL 30806323 A IL30806323 A IL 30806323A IL 308063 A IL308063 A IL 308063A
- Authority
- IL
- Israel
- Prior art keywords
- expanded
- dosing regimens
- integrin inhibitors
- integrin
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182757P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/072013 WO2022232838A1 (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308063A true IL308063A (en) | 2023-12-01 |
Family
ID=83848780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308063A IL308063A (en) | 2021-04-30 | 2022-04-29 | Expanded dosage regimens for integrin inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230028658A1 (https=) |
| EP (1) | EP4329755A4 (https=) |
| JP (1) | JP2024517765A (https=) |
| KR (1) | KR20240024060A (https=) |
| CN (1) | CN117615760A (https=) |
| AU (1) | AU2022265730A1 (https=) |
| CA (1) | CA3173787A1 (https=) |
| CL (1) | CL2023003219A1 (https=) |
| CO (1) | CO2023016295A2 (https=) |
| CR (1) | CR20230553A (https=) |
| IL (1) | IL308063A (https=) |
| MX (1) | MX2023012794A (https=) |
| TW (1) | TW202308637A (https=) |
| WO (1) | WO2022232838A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| CN114173803A (zh) | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| EP4247472A4 (en) | 2020-11-19 | 2024-10-09 | Pliant Therapeutics, Inc. | INTEGRIN INHIBITORS AND USES THEREOF |
| US20250197393A1 (en) | 2023-12-14 | 2025-06-19 | Pliant Therapeutics, Inc. | Integrin inhibitor and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2984394T3 (es) * | 2016-11-08 | 2024-10-29 | Bristol Myers Squibb Co | Compuestos mono y espirocíclicos que contienen ciclobutano y azetidina como inhibidores de la integrina alfa v |
| WO2019118938A1 (en) * | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| FI3761980T3 (fi) * | 2018-03-07 | 2024-02-21 | Pliant Therapeutics Inc | Aminohappoyhdisteitä ja käyttömenetelmiä |
| CN114173803A (zh) * | 2019-04-08 | 2022-03-11 | 普利安特治疗公司 | 氨基酸化合物的剂型和方案 |
| CN115989235A (zh) * | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| TW202329973A (zh) * | 2021-10-14 | 2023-08-01 | 美商普萊恩醫療公司 | 整合素抑制劑及其與其他藥劑併用之用途 |
-
2022
- 2022-04-29 MX MX2023012794A patent/MX2023012794A/es unknown
- 2022-04-29 IL IL308063A patent/IL308063A/en unknown
- 2022-04-29 WO PCT/US2022/072013 patent/WO2022232838A1/en not_active Ceased
- 2022-04-29 US US17/733,488 patent/US20230028658A1/en not_active Abandoned
- 2022-04-29 CR CR20230553A patent/CR20230553A/es unknown
- 2022-04-29 JP JP2023566804A patent/JP2024517765A/ja active Pending
- 2022-04-29 EP EP22796995.3A patent/EP4329755A4/en not_active Withdrawn
- 2022-04-29 CN CN202280046288.9A patent/CN117615760A/zh active Pending
- 2022-04-29 KR KR1020237041401A patent/KR20240024060A/ko not_active Withdrawn
- 2022-04-29 TW TW111116506A patent/TW202308637A/zh unknown
- 2022-04-29 AU AU2022265730A patent/AU2022265730A1/en not_active Abandoned
- 2022-04-29 CA CA3173787A patent/CA3173787A1/en active Pending
-
2023
- 2023-10-26 CL CL2023003219A patent/CL2023003219A1/es unknown
- 2023-11-29 CO CONC2023/0016295A patent/CO2023016295A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4329755A4 (en) | 2025-03-19 |
| CL2023003219A1 (es) | 2024-05-31 |
| MX2023012794A (es) | 2023-12-15 |
| TW202308637A (zh) | 2023-03-01 |
| CA3173787A1 (en) | 2022-11-03 |
| CN117615760A (zh) | 2024-02-27 |
| WO2022232838A1 (en) | 2022-11-03 |
| CR20230553A (es) | 2024-04-01 |
| US20230028658A1 (en) | 2023-01-26 |
| JP2024517765A (ja) | 2024-04-23 |
| EP4329755A1 (en) | 2024-03-06 |
| KR20240024060A (ko) | 2024-02-23 |
| CO2023016295A2 (es) | 2023-12-11 |
| AU2022265730A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308063A (en) | Expanded dosage regimens for integrin inhibitors | |
| IL280782A (en) | Inhibiting αv β6 integrin | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4007756C0 (en) | KIF18A INHIBITORS | |
| IL268947A (en) | Inhibitors of (alpha-v)(beta-6) integrin | |
| IL282545A (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| PL3578547T3 (pl) | Pochodne sulfonylomocznika i związki pokrewne oraz ich zastosowanie | |
| IL286145A (en) | Systems and methods for drug-agnostic patient-specific dosing regimens | |
| DK3844162T3 (da) | Hæmmere af alfa-v-beta6-integrin | |
| EP4313967C0 (en) | CHD Inhibitor | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4452967A4 (en) | SARS-CoV-2 INHIBITORS | |
| EP4226919A4 (en) | FERROPTOSIS INHIBITOR | |
| EP4210694A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4087845A4 (en) | BTK INHIBITORS | |
| EP4405334C0 (en) | Sortilin inhibitors | |
| JP1748149S (ja) | コンテナー | |
| IL280515A (en) | Dosing regimens for elagolix | |
| EP4101781A4 (en) | Container | |
| EP4080768A4 (en) | OSCILLATOR | |
| EP4448515A4 (en) | PLPRO INHIBITORS | |
| EP4433462A4 (en) | USP9X INHIBITORS | |
| EP4457223A4 (en) | BCL-2 INHIBITORS | |
| EP4178620A4 (en) | PLASMA KALLICREIN INHIBITORS |